Palovarotene Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 5 mg, 10 mg
Reference Brands: Sohonos (USA/EU)
Category:
Orphan Drugs
Palovarotene is available in Capsules
and strengths such as 5 mg, 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Palovarotene is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Palovarotene can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Palovarotene, marketed under the brand name Sohonos, is an oral medication indicated for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder that causes abnormal bone formation in muscles, tendons, and ligaments. As a highly selective retinoic acid receptor gamma (RARγ) agonist, palovarotene works by inhibiting the signaling pathways that lead to unwanted bone growth, helping to slow disease progression and preserve mobility.
Taken orally, Sohonos offers a targeted therapeutic option for patients suffering from FOP, a debilitating condition that severely impacts movement and quality of life. By addressing the underlying mechanism of abnormal bone formation, palovarotene provides hope for improved patient outcomes in a condition with limited treatment options. Its development as an orphan drug highlights its role in managing rare and serious skeletal disorders.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing